Reports Q2 revenue $6.865M vs $4.417M last year. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, “ETBs represent a novel approach to the treatment of cancer with differentiated biology and unique mechanisms of action. We expect to see substantial data across all three of our clinical programs with updates throughout this year and into 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MTEM:
- Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
- MTEM Earnings this Week: How Will it Perform?
- Indaptus Therapeutics appoints Waltzman as Chief Medical Officer
- Molecular Templates Announces Executive Leadership Changes
- Molecular Templates announces up to $40M private placement offering
